The Delhi High Court of India has upheld the patent of US pharma major Bristol Myers Squibs (NYSE: BMY) for Sprycel (dasatinib), reports The Economic Times of India.
The ruling dashes the hopes of a local company to sell a generic version of the cancer drug and provides some relief to multinational drugmakers who are up in arms against India's patent laws, the newspaper commented.
Justice Manmohan of the high court rejected Mumbai-based BDR Pharmaceuticals plea, which challenged the patent citing a provision in the Indian Patent Act that disallows evergreening of drugs. Evergreening is a practice by which holders of patents that are nearing expiry try to extend royalties, through steps such as taking new patents.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze